

PERSONS WITH PARKINSON'S DISEASE NEEDED FOR STUDY

The Speech Motor Systems Laboratory at the University of Massachusetts Amherst is looking for individuals with Parkinson's disease to participate in a study for decreased speaking volume. Qualified participants will be assigned to an eight-week voice treatment program. As a research participant, you will be asked to attend three sessions at the university campus, where you will be asked to perform various speaking and breathing exercises. Each session will last approximately 90-120 minutes. Free parking on campus will be provided.

To participate, you must meet the following criteria:

- Diagnosis of Parkinson's disease
- Problems with speech loudness due to Parkinson's disease
- No history of neurological disease, other than Parkinson's disease
- No asthma or respiratory problems (COPD, emphysema)
- No head, neck or chest surgery (Pacemaker surgery is okay)
- Non-smoking for the last 5 years
- Not currently participating in another treatment study
- Must be able to arrange transportation to and from campus
- Typical cognitive skills
- Free of symptoms of depression
- Healthy vocal folds
- No voice therapy or voice therapy maintenance within the last 12 months.

You will be compensated \$10/hour for participating in the laboratory sessions.

If you are interested in participating or would like more information, please contact Kelly Richardson at (413) 545-2007 or by email at krichardson@umass.edu.

Conflict of Interest Disclosure: The following disclosures are made to give you an opportunity to decide if these relationships will affect your willingness to participate in the research study. Dr. Huber, the co-investigator on the study, is the inventor of the SpeechVive™ device, which is one of the treatment programs being studied. She is on the Board of Directors of SpeechVive™, Inc, the company that manufactures and sells the SpeechVive™ device. She also owns stock in the company. Sandy Snyder, a staff member in Dr. Huber's laboratory, also owns stock in SpeechVive™, Inc. The researchers will not make any attempt to initiate the sale of the SpeechVive™ medical device either during the study or after study completion.